Adaptive Blood Purification for the Treatment of Patients With Septic Shock

Launched by BEIJING CHAO YANG HOSPITAL · Nov 14, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients admitted to intensive care unit (ICU), 18 years old ≤ age ≤ 82 years old;
• • 2. Meeting the diagnostic criteria for septic shock (Sepsis 3.0), and the onset time of septic shock ≤ 24 hours;
• • 3. Systemic inflammatory response syndrome (SIRS) ≥ 3 points;
• • 4. Sequential organ failure assessment (SOFA) ≥ 6 points;
• • 5. Voluntarily sign the informed consent form before the trial, and agree to participate in all visits, examinations, and treatments according to the requirements of the research plan.
• Exclusion Criteria:
• • 1. Patients who have received blood purification treatment within 1 week for any reason;
• • 2. Patients with congenital or acquired immunodeficiency diseases, or those who have received organ transplantation;
• • 3. Patients who have received immunosuppressive drugs (mycophenolate, cyclophosphamide, FK506, etc.) within 28 days before enrollment;
• • 4. Patients who received continuous treatment (≥ 3 days) with more than 10 mg/day of prednisolone (or other hormones at equivalent doses) within 28 days before enrollment;
• • 5. Patients with active bleeding (requiring blood transfusion \> 3 units in the past 24 hours);
• • 6. Patients with malignant tumors, those who cannot remove the lesions (such as surgical patients who cannot undergo surgical treatment);
• • 7. End-stage organ failure (end-stage pulmonary heart disease, brain death, chronic liver disease combined with hepatic encephalopathy);
• • 8. Platelet count \< 30×10\^9/L or neutrophil count \< 0.5×10\^9/L;
• • 9. Patients who require supportive treatment due to acute pulmonary embolism or severe congestive heart failure;
• • 10. The mean arterial blood pressure (MAP) cannot be maintained ≥ 65 mmHg after receiving vasoactive drugs and fluid resuscitation treatment;
• • 11. Patients who have participated or participated in another clinical study within 28 days before enrollment;
• • 12. Patients who are allergic to extracorporeal circulation materials, perfusion device materials or have a history of other severe allergies, or those who have heparin-associated thrombocytopenia;
• • 13. Patients who are inappropriate for participating, such as pregnant or lactating women, patients with severe mental and neurological diseases, and those with a history of alcoholism that cannot be terminated.